Pharmaceutical companies agree to reduce Medicare prices for 15 prescription drugs, potentially saving billions in taxpayer and patient costs under new negotiation rules starting in 2027.
China launches its first Commercial Health Insurance Innovative Drug List with CAR-T therapies, advancing access to innovative cancer and rare disease treatments under commercial insurance.
CMS has secured significant price reductions on 15 drugs including costly cancer treatments, impacting Medicare Part B pricing and healthcare costs.
CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.
CMS reveals new 2027 price caps for 15 Medicare Part D drugs, projected to save billions federally and reduce patient costs under the Inflation Reduction Act negotiations.
CMS announces $12 billion savings from Medicare drug price negotiations on 15 high-cost medications, effective 2027, enhancing Medicare Part D sustainability.
CMS sets 2027 maximum fair prices for 15 high-cost Medicare drugs, cutting costs by up to 85% and saving $12 billion annually under Inflation Reduction Act measures.
Novo Nordisk's semaglutide drugs face significant Medicare price reductions under CMS negotiation rules starting 2027, but new indications could drive future revenue growth.
Overview of US Congressional healthcare legislation, FDA's AI modernization, CMS payment reforms, and key trade agreements influencing the insurance landscape in 2025.
Hospitals challenge HHS's 340B pilot shifting drug discounts to a rebate system, citing financial risks and regulatory concerns.
